Aurobindo Pharma working on COVID-19 vaccine; shortlisted for BIRAC funding

"During the year (FY20), we have further strengthened our presence in the vaccines segment through the acquisition of RD assets from Profectus Biosciences through Auro Vaccines. Using those RD assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19," it said.